Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 14Breast 6Genitourinary 4Gastrointestinal 4Thoracic 3Head & Neck 3Dermatologic 2Plasma cell 1Other neoplasm 1NET 1Lymphoid 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 148Carcinoma, Neuroendocrine 57Thyroid Cancer, Papillary 54Pheochromocytoma 52Thyroid Neoplasms 42Paraganglioma 42Pituitary Neoplasms 39Neoplasms 32Adrenocortical Carcinoma 31Multiple Endocrine Neoplasia Type 1 29Gastro-enteropancreatic neuroendocrine tumor 29Thyroid Carcinoma, Anaplastic 24Lung Neoplasms 22Small Cell Lung Carcinoma 21Sarcoma 20Carcinoid Tumor 20Breast Neoplasms 19Neoplasm Metastasis 18Carcinoma, Non-Small-Cell Lung 18Adenoma, Islet Cell 18Melanoma 17Carcinoma, Hepatocellular 17Pancreatic Neoplasms 16Colorectal Neoplasms 16Adrenal Gland Neoplasms 16Prostatic Neoplasms 15Ovarian Neoplasms 15Neuroblastoma 15Carcinoma, Renal Cell 15Adenocarcinoma, Follicular 15

Interventions

Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Female × Endocrine × 1 year × Clear all
NCT04969887 2026-02-27

MOST-CIRCUIT

Olivia Newton-John Cancer Research Institute

Phase 2 Active not recruiting
240 enrolled
EndocrineNET

Genital Neoplasms, Female, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡